• Arcus Biosciences signed a clinical supply agreement with AVEO Oncology to test casdatifan with AVEO’s kidney cancer drug tivozanib.
• The combo will be evaluated in a new randomized ARC-20 cohort in advanced clear cell renal cell carcinoma previously treated with a HIF-2α inhibitor.
• Study design compares casdatifan with tivozanib 1.34 mg versus tivozanib 1.34 mg alone; AVEO supplies tivozanib.
• Arcus will sponsor and run the trial; each company retains development and commercial rights to its own drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720389288) on July 22, 2026, and is solely responsible for the information contained therein.